Henderson Mary Elizabeth 4
4 · Jazz Pharmaceuticals plc · Filed Mar 9, 2026
Research Summary
AI-generated summary of this filing
Jazz Pharmaceuticals SVP Mary Henderson Sells Shares to Cover Taxes
What Happened
Mary Elizabeth Henderson, Senior Vice President, Technical Operations at Jazz Pharmaceuticals (JAZZ), disposed of 1,394 ordinary shares on March 5, 2026. The weighted-average sale price reported was $186.75 per share, for proceeds of approximately $260,325. This transaction was a sale to satisfy tax obligations arising from the vesting of previously granted restricted stock units (RSUs), not an open-market investment buy.
Key Details
- Transaction date: March 5, 2026. Filing date: March 9, 2026. (Timeliness not specified in the provided data.)
- Shares sold: 1,394; weighted-average sale price: $186.75; total proceeds ≈ $260,325.
- Reason/code: F — shares sold to satisfy tax obligations on vested RSUs (Footnote F1).
- Footnote F2: Sales were executed in multiple transactions at prices ranging $186.1633–$186.7558; the filing reports the weighted-average price and the reporting person may provide transaction-level details upon request.
- Shares owned after the transaction: not specified in the provided filing excerpt.
Context
This was a routine tax-withholding sale tied to RSU vesting (cashless/tax-satisfaction event), which is common and generally not treated as a directional insider bet on the stock. For full details or to confirm filing timeliness, check the complete Form 4 on the SEC EDGAR system.
Insider Transaction Report
- Tax Payment
Ordinary Shares
[F1][F2]2026-03-05$186.75/sh−1,394$260,325→ 27,334 total
Footnotes (2)
- [F1]Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
- [F2]Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $186.1633 to $186.7558. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.